[
  {
    "ts": null,
    "headline": "Regeneron Pharmaceuticals, Inc. (REGN) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum Transcript",
    "summary": "Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum September 24, 2025 10:30...",
    "url": "https://finnhub.io/api/news?id=711b89b81518d64c06c64c6c0b7e6f7c1fffe9ae58c53eea17875b79f37ef6ef",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758721059,
      "headline": "Regeneron Pharmaceuticals, Inc. (REGN) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum Transcript",
      "id": 136863723,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "REGN",
      "source": "SeekingAlpha",
      "summary": "Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum September 24, 2025 10:30...",
      "url": "https://finnhub.io/api/news?id=711b89b81518d64c06c64c6c0b7e6f7c1fffe9ae58c53eea17875b79f37ef6ef"
    }
  },
  {
    "ts": null,
    "headline": "Amgen: Imdelltra Could Be The Next Game Changer",
    "summary": "Amgen: Imdelltra Could Be The Next Game Changer",
    "url": "https://finnhub.io/api/news?id=a15d953742da50b01f3453fd76eb35d73a9e11cbcaa6e56e032929c5a6813b78",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758709050,
      "headline": "Amgen: Imdelltra Could Be The Next Game Changer",
      "id": 136861111,
      "image": "",
      "related": "REGN",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=a15d953742da50b01f3453fd76eb35d73a9e11cbcaa6e56e032929c5a6813b78"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron’s Phase 2 COURAGE Trial Shows Trevogrumab Combination Preserves Lean Mass in Obesity Patients on Semaglutide",
    "summary": "Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the best innovative stocks to buy now. On September 17, Regeneron Pharmaceuticals announced updated analyses from the ongoing Phase 2 COURAGE trial for obesity. The complete 26-week results, which were presented as a late-breaking oral session at the 61st Annual Meeting of the European Association for the Study of […]",
    "url": "https://finnhub.io/api/news?id=f7816243902479258becad7ec5e9c7b1a29f021bf4be6eb0616e8d8aa14f69f7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758693477,
      "headline": "Regeneron’s Phase 2 COURAGE Trial Shows Trevogrumab Combination Preserves Lean Mass in Obesity Patients on Semaglutide",
      "id": 136861994,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the best innovative stocks to buy now. On September 17, Regeneron Pharmaceuticals announced updated analyses from the ongoing Phase 2 COURAGE trial for obesity. The complete 26-week results, which were presented as a late-breaking oral session at the 61st Annual Meeting of the European Association for the Study of […]",
      "url": "https://finnhub.io/api/news?id=f7816243902479258becad7ec5e9c7b1a29f021bf4be6eb0616e8d8aa14f69f7"
    }
  }
]